Iradimed Corp Stock Price, News & Analysis

IRADIMED CORPORATION announced preliminary financial results for Q3 2022, reporting approximately $13.4 million in revenue, a 23% increase from the prior year, surpassing guidance of $13.1 million - $13.3 million. This marks the company's highest revenue quarter and a continuation of a four-quarter trend of record revenues. However, the company voluntarily withdrew its 510(k) application for the MR IV pump due to the FDA's request for additional information, which they aim to resolve for a future resubmission.

IRADIMED CORPORATION (NASDAQ: IRMD) announced the appointment of Hilda Scharen-Guivel to its Board of Directors, effective October 4, 2022. With her extensive experience in regulatory oversight within the medical device industry, including her recent role at the FDA, her expertise is expected to be pivotal as the company develops new products. Following her appointment, the Board consists of five directors, three of whom are independent. IRADIMED specializes in MRI-compatible medical devices, and the addition of Scharen-Guivel may enhance the company’s growth trajectory.

IRADIMED CORPORATION (NASDAQ: IRMD) reported a record second quarter 2022 revenue of $12.7 million, marking a significant increase from $9.8 million in Q2 2021. Diluted GAAP EPS was $0.26, up from $0.12 year-over-year. For the six months ended June 30, revenue reached $25.0 million compared to $19.0 million in the same period in 2021. The company anticipates third-quarter guidance of $13.1 million to $13.3 million in revenue and full-year guidance of $52.5 million to $53.2 million.

IRADIMED CORPORATION (NASDAQ: IRMD) announced it will release its 2022 Q2 financial results on July 29, 2022, before the market opens. Management will hold a conference call at 11:00 a.m. ET the same day to discuss the results and answer questions. The call will be available online, and a recording will be accessible later on the company's website. IRADIMED is recognized for its innovative MRI-compatible medical devices, including the MRidium® IV infusion pump and 3880 vital signs monitoring system, designed to safely deliver anesthesia and monitor patients during MRI procedures.

IRADIMED CORPORATION (NASDAQ: IRMD) will announce its 2022 second quarter financial results on July 29, 2022, before market opening. A conference call will be held on the same day at 11:00 a.m. Eastern Time to discuss the results and answer questions from investors. Interested parties can register for the call via the provided link. The company specializes in MRI-compatible medical devices, notably its MRidium® IV infusion pump and the 3880 vital signs monitoring system, designed to enhance patient safety during MRI procedures. More details can be found on their official website.

Perimeter Medical Imaging AI has appointed Chris Scott as the new Chief Financial Officer, effective immediately. Scott brings extensive experience in the medtech sector, having previously served as CFO at iRadimed Corporation (NASDAQ: IRMD) and successfully led them through an IPO, increasing their market cap from $10 million to $600 million. The company is well-positioned with a strong balance sheet and is focused on further developing its S-Series OCT and next-gen AI technology.

IRADIMED CORPORATION (NASDAQ:IRMD) has appointed John (Jack) Glenn as its new Chief Financial Officer, effective on or before June 20, 2022. With over 30 years of experience in corporate finance, Glenn's expertise includes roles at Esko Bionics and Sonendo, as well as a strong background in the medical device sector. The company, recognized for its innovative MRI-compatible medical devices, aims to leverage Glenn's strategic financial management to support its ongoing growth trajectory, as stated by CEO Roger Susi.

IRADIMED CORPORATION (NASDAQ: IRMD) reported strong first-quarter 2022 results with revenue of $12.3 million, a significant increase from $9.2 million in Q1 2021. GAAP diluted earnings per share (EPS) reached $0.20, while non-GAAP diluted EPS was $0.22. The company announced a full-year revenue guidance increase to $52.5 million to $53.2 million and non-GAAP EPS guidance of $0.96 to $1.03. Domestic sales accounted for 81.1% of total revenue, indicating strong market demand. A special dividend of $1.00 per share was also declared.

IRADIMED CORPORATION (NASDAQ: IRMD) announced the resignation of Chris Scott, the Chief Financial and Operating Officer, effective May 27, 2022. Scott has been with the company since December 2013 and is leaving to pursue other opportunities. Matt Garner, the Controller, will take on the role of interim CFO during the transition. CEO Roger Susi expressed gratitude for Scott's contributions over the years and confidence in Garner's ability to lead the finance department. A formal search for a new CFO is underway.